ClinicalTrials.gg
CompletedNCT05329259Updated Apr 26, 2024Results posted

A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India

A Phase 4 interventional study of 13-valent pneumococcal conjugate vaccine in Pneumococcal Disease, sponsored by Pfizer. Completed at 5 sites in India. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-26.

Sponsored by Pfizer · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.

Enrollment
33rd of 44
200 · median 328
Started
2022
with 2 others
Phase 4
11 of 44
none open now
Registered
40th of 44
by date
Lead sponsor
16 of 44
Pfizer

Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 33rd largest by enrollment, is one of 3 that started in 2022, is one of 11 in phase 4, and was the 40th registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →

About 13-valent pneumococcal vaccine

13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections as a file.
02

Study summary

  • The purpose of this study is to describe the safety of the study vaccine (called 13vPnC) in people who are 18-49 years of age in India.
  • This study is seeking participants who are generally healthy adults ≥18 and \<50 years of age, with no prior history of pneumococcal vaccination.
  • Participants will take part in the study for approximately one month which includes two visits to the study clinic.
  • Participants will receive a single dose of study vaccine (13vPnC) into the arm at visit 1 and will come to study site for a follow-up visit after about a month.
03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Generally healthy participants between the ages of ≥18 and \<50 years at the time of consent.
  • Participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.

Exclusion criteria

Exclusion Criteria:

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of 13vPnC, or to any other diphtheria toxoid-containing vaccine.
  • Congenital, functional, or surgical asplenia.
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Previous vaccination with any pneumococcal vaccine, or planned receipt of any pneumococcal vaccine through study participation.
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    13-valent pneumococcal conjugate vaccine

    Pneumococcal conjugate vaccine (13vPnC)

    Biological: 13-valent pneumococcal conjugate vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Prompted Local Reactions Within 7 Days After Vaccination

    From Day 1 through Day 7 following vaccination, where Day 1 is the day of vaccination, local reactions including redness, swelling, and pain at the injection site were assessed and recorded.

    Time frame: Within 7 Days After Vaccination

  2. Percentage of Participants With Prompted Systemic Events Within 7 Days After Vaccination

    From Day 1 through Day 7 following vaccination, where Day 1 is the day of vaccination, systemic events including fever, headache, fatigue, muscle pain, and joint pain were assessed and recorded. Fever was defined as temperature ≥38.0 °C.

    Time frame: Within 7 Days After Vaccination

  3. Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination

    An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Local reactions (redness, swelling, and pain at the injection site) and systemic events (fever, headache, fatigue, muscle pain, and joint pain) were not collected as AEs.

    Time frame: Within 1 Month After Vaccination

  4. Percentage of Participants With Serious Adverse Events (SAEs) Within 1 Month After Vaccination

    An SAE was any untoward medical occurrence at any dose that resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or considered to be an important medical event.

    Time frame: Within 1 Month After Vaccination

07

Results

Posted Apr 26, 2024

Participant flow

This study was conducted in India. Participants took part in the study for approximately 1 month.

Vaccination Period
Participant flow — Vaccination Period
Milestone13vPnC
Started200
Completed200
Not completed0
1-Month Follow-Up Period
Participant flow — 1-Month Follow-Up Period
Milestone13vPnC
Started200
Completed200
Not completed0

Outcome measures

PrimaryPercentage of Participants With Prompted Local Reactions Within 7 Days After Vaccination

From Day 1 through Day 7 following vaccination, where Day 1 is the day of vaccination, local reactions including redness, swelling, and pain at the injection site were assessed and recorded.

Time frame:
Within 7 Days After Vaccination
Reported as:
Number · Percentage
Percentage of Participants With Prompted Local Reactions Within 7 Days After Vaccination
Percentage13vPnC
Redness1.5 (0.3 to 4.3)
Swelling6.5 (3.5 to 10.9)
Pain at Injection Site63.0 (55.9 to 69.7)
PrimaryPercentage of Participants With Prompted Systemic Events Within 7 Days After Vaccination

From Day 1 through Day 7 following vaccination, where Day 1 is the day of vaccination, systemic events including fever, headache, fatigue, muscle pain, and joint pain were assessed and recorded. Fever was defined as temperature ≥38.0 °C.

Time frame:
Within 7 Days After Vaccination
Reported as:
Number · Percentage
Percentage of Participants With Prompted Systemic Events Within 7 Days After Vaccination
Percentage13vPnC
Fever3.0 (1.1 to 6.4)
Fatigue25.0 (19.2 to 31.6)
Headache23.0 (17.4 to 29.5)
Joint Pain7.5 (4.3 to 12.1)
Muscle Pain32.0 (25.6 to 38.9)
PrimaryPercentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination

An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Local reactions (redness, swelling, and pain at the injection site) and systemic events (fever, headache, fatigue, muscle pain, and joint pain) were not collected as AEs.

Time frame:
Within 1 Month After Vaccination
Reported as:
Number · Percentage
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination
Percentage13vPnC
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination0.5 (0.0 to 2.8)
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) Within 1 Month After Vaccination

An SAE was any untoward medical occurrence at any dose that resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or considered to be an important medical event.

Time frame:
Within 1 Month After Vaccination
Reported as:
Number · Percentage
Percentage of Participants With Serious Adverse Events (SAEs) Within 1 Month After Vaccination
Percentage13vPnC
Percentage of Participants With Serious Adverse Events (SAEs) Within 1 Month After Vaccination0 (0 to 1.8)

Adverse events

Collected over Within 1 month after vaccination.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC0/200 (0%)0/200 (0%)1/200 (0.5%)
Most frequent other events
Most frequent other events
Event13vPnC
VaricellaInfections and infestations1/200

Baseline characteristics

All participants who received any study intervention and had safety data assessed after vaccination.

Age, Continuous
Age, Continuous(Years)13vPnC
Mean31.4 ± 7.98
Age, Continuous
Age, Continuous(Years)13vPnC
Median29.0 (18 to 49)
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC
Female92
Male108
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)13vPnC
Race_Asian200
Ethnicity_Non-Hispanic/Non-Latino200
08

Study locations

5 sites
  • Nirmal Hospital Pvt Ltd.
    Surat, Gujarat 395002, India
  • BGS Global Institute of Medical Sciences (BGSGIMS)
    Bangalore, Karnataka 560060, India
  • Jawahar Lal Nehru Medical College
    Ajmer, Rajasthan 305001, India
  • Calcutta School of Tropical Medicine
    Kolkata, WEST Bengal 700073, India
  • Aakash Healthcare Private Limited
    Delhi, 110075, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Nov 2022, 1 month.

Results were first posted in Apr 2024, 1 year 4 months after primary completion.

Of 21 phase 4 interventional studies under Pneumococcal Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 44. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2022
First posted
Apr 14, 2022
StartActual
Oct 6, 2022
Primary completionActual
Nov 30, 2022
CompletionActual
Nov 30, 2022
Results first posted
Apr 26, 2024
Last update
Apr 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05329259
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 14, 2022
Start date
Oct 6, 2022
Primary completion
Nov 30, 2022
Completion
Nov 30, 2022
Results posted
Apr 26, 2024
Last update
Apr 26, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion